MedTrace Logo

Iron Supplementation in Schistosomiasis and Soil Transmitted Helminths Control Programmes in Zambia

NCT00276224 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 480

Last updated 2007-10-31

No results posted yet for this study

Summary

The objectives of this study is:

* to establish the coverage rate of weekly iron supplementation in children in intervention schools over a period of nine months
* document any side effects of weeekly iron supplementation among children in intervention schools over a period of nine months asses the feasibility of incorporating the weekly iron supplementation programme into the normal school activity in intervention schools determine the extent of acceptability and support for the iron supplementation programme by staff at the health centre nearest to the intervention schools
* compare the praziquantel efficacy and schistosomiasis reinfection in children in intervention schools with that of children in control schools following the introduction of weekely iron supplementation over a period of nine months
* determine the impact of weekly iron supplementation on haemoglobin levels of children in intervention schools and compare with children in control schools over a period of nine months

Conditions

  • Schistosomiasis
  • Helminthiases
  • Anaemia

Interventions

DRUG

ferrous sulphate (drug)

Sponsors & Collaborators

  • DBL -Institute for Health Research and Development

    lead OTHER

Principal Investigators

  • Victor Mwanakasale, Ph.d.,M.Sc. · Tropical Disease Research Centre, Ndola, Zambia

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
9 Years
Max Age
15 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-09-30
Completion
2006-04-30

Countries

  • Zambia

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00276224 on ClinicalTrials.gov